Related Experiment Videos
Expression of Novel CD44st and MMP2 in NSCLC Tissues and Their Clinical Significance
Background:
Abnormal expression of some CD44 molecules in tumor tissues can induce the degradation of the extracellular matrix, and is closely associated with axillary lymph node metastasis, angiogenesis, cancer progression, and drug resistance.
Patients And Methods:
We measured and confirmed the expression of CD44st and MMP2 mRNAs and proteins in the cancer tissues and adjacent normal tissues of postoperative non-small cell lung cancer (NSCLC) patients with either adenocarcinoma (n = 72) or squamous cell carcinoma (n = 53) using quantitative reverse transcription polymerase chain reaction, gene sequencing, and immunohistochemical analysis.
Results:
CD44st and MMP2 expression were closely associated with the histopathological classification, lymph node metastasis, and TNM stage of the tumors, and the difference was statistically significant (p < 0.05). The median overall survival (OS) for the high CD44st expression group was 30.52 months (95% confidence interval (CI) 24.02-36.15); for the low expression group it was 43.23 months (95% CI 31.81-52.02) (p = 0.020). The median OS for the high MMP-2 expression group was 30.53 months (95% CI 26.69-33.31); for the low expression group it was 40.06 months (95% CI 33.55-46.45) (p = 0.022).
Conclusion:
The rates of CD44st and MMP2 expression were higher in squamous cell carcinomas than in adenocarcinomas, were closely associated with lymph node metastasis and TNM stage, and affected patients' prognoses.
Insights
High CD44 standard (CD44st) and matrix metalloproteinase-2 (MMP2) expression in non-small cell lung cancer (NSCLC) correlates with advanced disease and poorer survival. Targeting these markers may improve patient outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Aberrant CD44 variant expression in tumors promotes extracellular matrix degradation, influencing metastasis, angiogenesis, cancer progression, and drug resistance.
- CD44 standard (CD44st) and matrix metalloproteinase-2 (MMP2) are implicated in various cancer hallmarks.
Purpose of the Study:
- To investigate the expression levels of CD44st and MMP2 in non-small cell lung cancer (NSCLC) tissues.
- To determine the association of CD44st and MMP2 expression with clinicopathological features and patient prognosis in NSCLC.
Main Methods:
- Quantitative reverse transcription polymerase chain reaction, gene sequencing, and immunohistochemical analysis were used.
- Expression of CD44st and MMP2 mRNAs and proteins was measured in cancer and adjacent normal tissues from NSCLC patients (adenocarcinoma n=72, squamous cell carcinoma n=53).
Main Results:
- CD44st and MMP2 expression significantly correlated with histopathological classification, lymph node metastasis, and TNM stage (p < 0.05).
- Patients with high CD44st expression had a median overall survival (OS) of 30.52 months, versus 43.23 months for low expression (p = 0.020).
- High MMP2 expression was associated with a median OS of 30.53 months, compared to 40.06 months for low expression (p = 0.022).
Conclusions:
- CD44st and MMP2 expression rates were higher in squamous cell carcinomas than adenocarcinomas.
- Elevated CD44st and MMP2 expression are linked to lymph node metastasis and advanced TNM stage in NSCLC.
- These markers significantly impact patient prognosis, suggesting their potential as prognostic biomarkers.